Aphria Introduces Dr. Jonathan Simone, PhD as Director of Research and Clinical Studies
October 25, 2018
Dr. Simone is recognized for his award-winning research on the role of the endocannabinoid system in neurodevelopment, and in the regulation of affective and cognitive behaviours
Leamington, Ontario – October 25, 2018 – Aphria Inc. (“Aphria” or the “Company“) (TSX: APH and US OTC: APHQF) today officially introduced Dr. Jonathan Simone, PhD as the Company’s Director of Research and Clinical Studies. Dr. Simone joined Aphria in July 2018 and serves as the primary liaison between the Company’s science, technical and medical division teams and outside medical, academic and clinical centers. He is also spearheading Aphria’s participation in various clinical studies.
“As the post-legalization era unfolds, Aphria remains committed to supporting our patients and the advancement of medical cannabis around the world through much-needed clinical research studies,” said Vic Neufeld, Chief Executive Officer of Aphria. “Jonathan is a rising star in the medical cannabis research community and we are pleased to welcome him to the Aphria family. He is uniquely qualified to accelerate Aphria’s support for and participation in medical cannabis clinical research to further the Company’s continued global leadership in medical cannabis.”
Dr. Simone recently completed his PhD in Neurobiology and Physiology at Brock University in St. Catharines, Ontario where he was instrumental in the development of an award-winning, multi-disciplinary cannabinoid research program. His research into the neurobiology and behavioural pharmacology of cannabinoids and the endocannabinoid system has been recognized both nationally and internationally with awards from organizations including the Canadian Consortium for the Investigation of Cannabinoids (CCIC), the International Cannabinoid Research Society (ICRS), the Natural Sciences and Engineering Research Council of Canada(NSERC), and the Canadian College of Neuropsychopharmacology (CCNP), Dr. Simone’s research has been consistently published in high-quality, peer-reviewed scientific journals and presented at scientific conferences around the world. In July 2018, his research into the role of the endocannabinoid system in social behaviour development was awarded the Scientific Achievement Award at the 28th Annual ICRS Symposium on the Cannabinoids in Leiden, Netherlands.
“I am thrilled to be part of an organization that is leading the global medical cannabis industry through an uncompromising commitment to quality, integrity, accountability, and above all else, a dedication to the well-being of their patients,” said Dr. Simone. “Through rigorous, high-quality research collaborations with world-class medical and academic partners, we will work tirelessly to generate new cannabis knowledge, drive new product innovation, and most importantly, validate the use of cannabis as medicine.”
Dr. Simone has served as an expert-reviewer for several high-impact scientific journals and has been an invited guest lecturer in various university classrooms to speak on topics related to cannabis and cannabinoids. Jonathan is also a certified horticulturist with several years of commercial and retail greenhouse management experience, providing him a unique background from which to guide Aphria’s clinical research program.
We Have A Good Thing Growing
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.
For more information, visit: aphria.ca
For media inquiries please contact:
Vice President, Communications
For investor inquiries please contact:
Vice President, Investor Relations
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations with respect to actual production volumes, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.